Posted by Michael Wonder on 30 Sep 2021
Prime Therapeutics and Pear Therapeutics announce first comprehensive value based agreement for prescription digital therapeutics reSET and reSET-O for the treatment of substance and opioid use disorders
29 September 2021 - Agreement aims to reduce inpatient hospitalisations and total cost of care.
Prime Therapeutics and Pear Therapeutics have developed a comprehensive value based agreement for prescription digital therapeutics (PDTs).
This value-based agreement for Pear’s PDTs is the first of its kind to feature three outcome measures (hospital inpatient stay, total health care cost and physician product engagement).
